Greenwich LifeSciences (GLSI) Earnings Date & Reports

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

GLSI is expected to report earnings to fall 4.17% to -23 cents per share on August 14

Greenwich LifeSciences GLSI Stock Earnings Reports

Q2'23

Est.

$-0.23

Q1'25

Missed

by $0.03

Q4'24

Missed

by $0.40

Q2'24

Est.

$-0.20

Q1'24

Beat

by $0.01

The last earnings report on May 19 showed earnings per share of -23 cents, missing the estimate of -20 cents. With 337.00 shares outstanding, the current market capitalization sits at 120.05M.

View a ticker or compare two or three

Compare

GLSI